HC Wainwright Reiterates Buy Rating for Strongbridge Biopharma PLC (SBBP)

Strongbridge Biopharma PLC (NASDAQ:SBBP)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report released on Wednesday.

A number of other brokerages also recently issued reports on SBBP. Zacks Investment Research downgraded Strongbridge Biopharma PLC from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. ValuEngine downgraded Strongbridge Biopharma PLC from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Finally, Oppenheimer Holdings, Inc. assumed coverage on Strongbridge Biopharma PLC in a research report on Thursday, August 10th. They set an “outperform” rating and a $12.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $11.81.

Shares of Strongbridge Biopharma PLC (NASDAQ:SBBP) opened at $5.75 on Wednesday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 4.46 and a current ratio of 4.63. Strongbridge Biopharma PLC has a 52-week low of $2.00 and a 52-week high of $8.85.

COPYRIGHT VIOLATION NOTICE: “HC Wainwright Reiterates Buy Rating for Strongbridge Biopharma PLC (SBBP)” was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://transcriptdaily.com/2017/11/15/hc-wainwright-reiterates-buy-rating-for-strongbridge-biopharma-plc-sbbp.html.

Several large investors have recently modified their holdings of SBBP. Lyon Street Capital LLC acquired a new stake in shares of Strongbridge Biopharma PLC during the 3rd quarter worth about $2,862,000. Northern Trust Corp acquired a new position in Strongbridge Biopharma PLC in the 2nd quarter valued at about $1,462,000. Caxton Corp grew its position in Strongbridge Biopharma PLC by 2.2% in the 3rd quarter. Caxton Corp now owns 5,514,994 shares of the biotechnology company’s stock valued at $38,053,000 after acquiring an additional 120,000 shares in the last quarter. Nexthera Capital LP acquired a new position in Strongbridge Biopharma PLC in the 2nd quarter valued at about $477,000. Finally, Vanguard Group Inc. acquired a new position in Strongbridge Biopharma PLC in the 2nd quarter valued at about $474,000. 56.53% of the stock is owned by hedge funds and other institutional investors.

About Strongbridge Biopharma PLC

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply